Pacific Biosciences of California, Inc. (PACB)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$1.35+3.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
PacBio is improving its gross profit, reaching $12.8M in Q1 2026 from a loss last year. Revenue is expected to grow about 13% in 2026 to $170M. New sequencing chemistry cuts genome costs, supporting sales growth. The company is managing costs and progressing toward profitability.
PacBio remains unprofitable with negative EPS expected through 2027. Recent guidance cuts and CFO departure raise concerns. Revenue growth and margin improvements may stall, risking further losses and cash flow problems.
The market prices in about 14% revenue growth and values the stock roughly 13% above our fair value near $1.43. Our view aligns with consensus on growth but remains cautious on sustained profitability.
Breaks if: Gross profit falls below $10M in any quarter after 2026-Q1
Management is focused on improving gross profit margins over time.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a volatile management track record, which adds to the uncertainty surrounding its future performance.
The market seems to price PACB as cheap compared to its peers, but there is a negative expectations gap. Investors may be cautious given the company's recent shift from robust to fragile performance.
Management is on track to achieve its revenue guidance and reduce operating expenses, but the trajectory of these efforts is still in early stages. Recent financial performance has been neutral, with slight growth, but risks remain elevated.
The long-term thesis hinges on management's ability to execute on revenue and cost reduction goals. Additionally, the performance of larger healthcare companies could influence PACB's momentum positively or negatively.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The reason to own PACB has diminished due to recent financial performance. It dropped from the robust half to the weak half of its sector. Additionally, the company lowered its revenue forecast for 2026, impacting growth objectives. However, there are advancements in the commercial rollout of SPRQ-Nx chemistry and new leadership that may drive strategic growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Departure of CEO or CFO within next 12 months
Breaks if: Revenue falls below $160M in FY26
Overall, PACB's outlook is uncertain as it navigates management changes and sector conditions. Not investment advice.